American Society of Hematology | International Myeloma Foundation

January 8

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1–3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Sequential T-Cell Engagement for Myeloma (“STEM”) Trial: A Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy

ASH

January 8

The STEM Trial Phase II Study on Cevostamab Consolidation After BCMA CAR T-Cell Therapy

$BMS-986393 (CC-95266), a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study$

ASH

January 8

Updates in Myeloma Treatment: BMS-986393 CAR T-Cell Therapy Shows Promise in Phase I Study for Relapsed/Refractory Patients

Hospital staff claps as African American senior in wheelchair is released

Clinical Trials and Treatments

May 5

Studies on Disparities in Myeloma Presented at ASH

Patient & Family Webinar

February 26

From Best of 2021 ASH to 2022 COVID-19 Guidance

iStopmm Study abstracts being presented at ASH 2021

Ask Dr. Durie

December 8

How important are the four iStopMM abstracts being presented at ASH for myeloma patients?

Week in Review

December 2

ASH Meeting Collides With Emergence of Omicron Variant

ASH

January 14

Top Myeloma Takeaways From the 2020 American Society of Hematology Meeting

Ask Dr. Durie blog: American Society of Hematology Blog

Week in Review

November 12

ASH 2020: Building Toward the Future of Myeloma Care

ASCO/EHA

June 25

Top Myeloma Research Presented at ASCO and EHA 2020

Week in Review

November 7

ASH Top 10 for 2019: Immune therapies again dominate the news

Interior of the San Diego convention center for ASH 2019

Week in Review

January 12

Future Myeloma Therapy—We Plan, God Laughs

Share On

Donation

Give Where Most Needed